ATTAIN STUDY ACLIDINIUM PDF

The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). David Singh, Eric D. Bateman, Paul W. Jones. The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eric D. Bateman, David Singh, Paul W. Jones, Alvar. This paper presents results from a phase III study of longer duration (Aclidinium To Treat Airway obstruction In COPD patieNts; ATTAIN), which.

Author: Faesida Mezilkis
Country: Tunisia
Language: English (Spanish)
Genre: Video
Published (Last): 5 November 2004
Pages: 355
PDF File Size: 15.33 Mb
ePub File Size: 7.90 Mb
ISBN: 974-5-52859-912-5
Downloads: 22123
Price: Free* [*Free Regsitration Required]
Uploader: Mezishura

The three LAMAs also provide patients with a choice, as each is delivered by a different device, and some patients may prefer one over another. Preclinical and pharmacological studies demonstrating low systemic bioavailability and a low propensity to induce cardiac arrhythmias were translated into a favorable tolerability profile in the clinical trial program — the adverse event profile of aclidinium was similar to placebo, with a low incidence of anticholinergic and cardiac adverse events.

Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs. Author information Copyright and License information Disclaimer.

Aclidinium bromide provides long-acting bronchodilation in patients with COPD. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. Food and Drug Administration Tudorza Pressair: Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.

Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery.

Global Initiative for Chronic Obstructive Lung Disease [webpage on the Internet] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [updated Jan ] [Accessed November 12, ].

Mean area under the FEV 1 curve 0—24 h time interval was 1. The author and his institution have received consulting and lecture fees from Almirall S.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

stufy Phase II Joos et al Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials. A phase I, open-label, single-dose clinical trial. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Reproduced with permission of Informa Healthcare. That may be the case with aclidinium. In conclusion, when considering new inhaled drugs, it is important to look beyond the chemical entity and its pharmacology.

  HADRAH BASAUDAN PDF

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

acldiinium Summary review of regulatory action. Furthermore, a higher proportion of patients treated with aclidinium achieved the MCID in each of these measures, compared with placebo. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: However, these studies were not designed to directly compare the two doses, and confidence intervals often overlapped. Reproduced with permission of the European Respiratory Society: Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.

Preclinical studies have shown that aclidinium displays high affinity for all five muscarinic receptors, with kinetic selectivity for M 3 receptors over M 2and a shorter duration of action and a faster onset compared with tiotropium bromide.

The subject of this review is a third LAMA, aclidinium bromide, which was approved as a twice-daily maintenance bronchodilator treatment.

US Food and Drug Administration; Twice-daily aclidinium bromide in COPD patients: In the ACCORD COPD I study, 31 night-time and morning COPD symptoms were all significantly reduced among patients treated with aclidinium compared with those who received placebo Figure 5and the impact of breathlessness on early morning activities was also significantly reduced with aclidinium versus placebo Figure 6.

Three long-acting muscarinic antagonists LAMAs aclidiniu, now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease.

What stands out as the difference between it and them, since they seem to have artain efficacy and safety profiles? Tiotropium versus placebo for chronic obstructive pulmonary disease.

COPD Efficacy Study | TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder)

J Pharmacol Exp Ther. Well tolerated, no anticholinergic side effects reported, no clinical effect on EKG parameters. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD.

  KYRIL BONFIGLIOLI PDF

While additional studies are needed to evaluate its full clinical potential, aclidinium is an important part of this recent expansion of LAMA therapeutic options, providing clinicians and patients with an effective and well-tolerated COPD treatment.

The full terms of the License are available at http: Safety and tolerability of aclidinium bromide in patients with COPD: In the pivotal Phase III clinical trials, patients receiving aclidinium achieved significantly greater improvements in lung function, reductions in breathlessness, and improvements in health status compared with placebo, for up to 24 weeks. Published online Mar Int J Clin Pharmacol Ther.

Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Pooled data showed exacerbation frequency was attaim reduced with aclidinium versus placebo. Study acronym and reference Study treatments N Duration weeks Sclidinium efficacy results treated vs placebo, attxin However, the acliidinium of decline in FEV 1 — the primary outcome of the trial — was not significantly reduced by the use of tiotropium.

Eur Respir JOctober Glycopyrronium bromide Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery.

Inhaler mishandling remains stydy in real life and is associated with reduced disease control. Breathlessness, health status, and COPD symptoms with aclidinium Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials.

Expert Opin Drug Deliv.

Discussion As noted in the current GOLD guidelines, tiotropium, aclidinium, and glycopyrronium can all be considered as appropriate options for maintenance treatment in the stable COPD patient. Reduced COPD exacerbations associated with aclidinium bromide versus placebo: